SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.930
+0.120 (4.27%)
Dec 3, 2024, 1:41 PM EST - Market open

SAB Biotherapeutics Revenue

SAB Biotherapeutics had revenue of $1.51M in the twelve months ending September 30, 2024, down -63.06% year-over-year. In the year 2023, SAB Biotherapeutics had annual revenue of $2.24M, down -90.63%.

Revenue (ttm)
$1.51M
Revenue Growth
-63.06%
P/S Ratio
16.03
Revenue / Employee
$26,539
Employees
57
Market Cap
27.04M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20232.24M-21.67M-90.63%
Dec 31, 202223.90M-36.97M-60.73%
Dec 31, 202160.88M5.64M10.21%
Dec 31, 202055.24M51.80M1,504.91%
Dec 31, 20193.44M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Equillium 45.91M
Bionano Genomics 33.33M
DarioHealth 23.05M
BioLineRx 21.99M
DURECT 8.59M
Co-Diagnostics 7.32M
NeurAxis 2.46M
CytoMed Therapeutics 330.25K
Revenue Rankings